Browsing Category

MENA

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk

CGTN: China-Europe Ties: Shaping the Next 50 Years

CGTN: China-Europe Ties: Shaping the Next 50 Years BEIJING, Dec. 04, 2025 (GLOBE NEWSWIRE) — This year marks the 50th anniversary of the establishment of diplomatic relations between China and the European Union – a